JP7787811B2 - MrgprX2アンタゴニストおよびその使用 - Google Patents

MrgprX2アンタゴニストおよびその使用

Info

Publication number
JP7787811B2
JP7787811B2 JP2022526331A JP2022526331A JP7787811B2 JP 7787811 B2 JP7787811 B2 JP 7787811B2 JP 2022526331 A JP2022526331 A JP 2022526331A JP 2022526331 A JP2022526331 A JP 2022526331A JP 7787811 B2 JP7787811 B2 JP 7787811B2
Authority
JP
Japan
Prior art keywords
compound
composition
alkyl
skin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022526331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554392A (ja
JP2022554392A5 (cg-RX-API-DMAC7.html
Inventor
フェルダ チェビクバシュ
クリストファー ピアソン
ローラ グリーブ
ニーナ コネリー ウルシニョバ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermira Inc
Original Assignee
Dermira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermira Inc filed Critical Dermira Inc
Publication of JP2022554392A publication Critical patent/JP2022554392A/ja
Publication of JP2022554392A5 publication Critical patent/JP2022554392A5/ja
Application granted granted Critical
Publication of JP7787811B2 publication Critical patent/JP7787811B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022526331A 2019-11-05 2020-11-05 MrgprX2アンタゴニストおよびその使用 Active JP7787811B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962931186P 2019-11-05 2019-11-05
US62/931,186 2019-11-05
US201962931576P 2019-11-06 2019-11-06
US62/931,576 2019-11-06
US202063046481P 2020-06-30 2020-06-30
US63/046,481 2020-06-30
PCT/US2020/059228 WO2021092264A1 (en) 2019-11-05 2020-11-05 MrgprX2 ANTAGONISTS AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2022554392A JP2022554392A (ja) 2022-12-28
JP2022554392A5 JP2022554392A5 (cg-RX-API-DMAC7.html) 2023-10-31
JP7787811B2 true JP7787811B2 (ja) 2025-12-19

Family

ID=73740488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526331A Active JP7787811B2 (ja) 2019-11-05 2020-11-05 MrgprX2アンタゴニストおよびその使用

Country Status (8)

Country Link
US (1) US20230002336A1 (cg-RX-API-DMAC7.html)
EP (1) EP4055011A1 (cg-RX-API-DMAC7.html)
JP (1) JP7787811B2 (cg-RX-API-DMAC7.html)
CN (1) CN114728919B (cg-RX-API-DMAC7.html)
AU (1) AU2020380926B2 (cg-RX-API-DMAC7.html)
CA (1) CA3159633A1 (cg-RX-API-DMAC7.html)
IL (1) IL292693B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021092264A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850094B (zh) * 2022-09-07 2025-02-11 北华航天工业学院 一种利用1,2-环氧丁烷合成β-氨基醇的方法
WO2025002360A1 (zh) * 2023-06-30 2025-01-02 北京普祺医药科技股份有限公司 一种mrgprx2拮抗剂、药物组合物以及其用途
US20250084063A1 (en) 2023-08-18 2025-03-13 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025160430A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025163462A1 (ko) * 2024-02-02 2025-08-07 삼진제약주식회사 헤테로고리를 갖는 mrgprx2((mas-related g-protein coupled receptor member x2) 길항제 유도체와 이의 용도
WO2025222076A1 (en) 2024-04-19 2025-10-23 Kyorin Pharmaceutical Co., Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as mrgprx2 antagonists for the treatment of inflammatory diseases
WO2025222040A1 (en) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige
US12630562B2 (en) 2024-08-07 2026-05-19 Arcus Biosciences, Inc. Piperidylurea compounds and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520162A (ja) 2007-02-28 2010-06-10 スミスクライン ビーチャム コーポレーション ステアロイル−CoAデサチュラーゼ阻害剤であるチアジアゾール誘導体

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152442A (en) * 1975-06-05 1979-05-01 Lilly Industries Limited Certain acylamino-oxa (or thia) diazoles in treatment of hypersensitivity conditions
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
EP0084665B1 (de) * 1982-01-22 1986-08-13 BASF Aktiengesellschaft Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
GB0308511D0 (en) * 2003-04-14 2003-05-21 Astex Technology Ltd Pharmaceutical compounds
BRPI0413709A (pt) * 2003-08-21 2006-10-17 Pfizer Prod Inc compostos para o tratamento de distúrbios neurodegenerativos
DE102004009933A1 (de) * 2004-02-26 2005-09-15 Merck Patent Gmbh Verwendung von Thiadiazolharnstoffderivaten
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2725022B1 (de) * 2008-06-13 2017-03-29 Bayer CropScience AG Neue Amide als Schädlingsbekämpfungsmittel
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
US8377639B2 (en) * 2009-06-26 2013-02-19 University Of Massachusetts Compounds for modulating RNA binding proteins and uses therefor
RU2601550C2 (ru) * 2010-12-09 2016-11-10 Вокхардт Лимитед Кетолидные соединения
JP6130383B2 (ja) * 2011-09-30 2017-05-17 エンドゥ ファーマシューティカルズ,インコーポレイティド ピリジン誘導体
CN104955332B (zh) * 2013-01-30 2017-03-29 住友化学株式会社 防治节足害虫的方法
WO2015089327A1 (en) * 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CN107001362A (zh) * 2014-10-06 2017-08-01 默克专利有限公司 用作btk抑制剂的杂芳基化合物及其用途
BR112019018230A2 (pt) * 2017-03-02 2020-07-21 Assembly Biosciences, Inc. compostos de sulfamida cíclica e métodos de sua utilização

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520162A (ja) 2007-02-28 2010-06-10 スミスクライン ビーチャム コーポレーション ステアロイル−CoAデサチュラーゼ阻害剤であるチアジアゾール誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAS登録番号2373852-96-9、2373785-27-2、2372800-30-9、2305355-17-1、2072967-38-3、2072939-65-0、2072672-14-9、2072641-65-5、2072573-66-9、2072573-53-4、2072445-40-8、2072231-63-9、2072216-64-7、2072182-30-8、2072009-87-9、2071773-48-1、2071656-21-6、2071601-36-8、2071485-23-7、2071484-66-5、2071003-29-5、2069575-25-1、2069318-09-6、2069173-62-0、2068939-44-4、2068938-31-6、2068673-72-1、2060949-80-4、2059876-46-7、1797794-23-0、1795510-24-5、1389735-91-4、1355717-46-2、1087583-65-0、881939-98-6,REGISTRY(STN)[online],2019年09月04日,[検索日 2025.02.13]
CAS登録番号380155-27-1、1355700-96-7、1957160-15-4、2179112-66-2、345614-53-1、2301679-05-8、2060999-00-8,REGISTRY(STN)[online],2019年04月05日,[検索日 2024.09.25]

Also Published As

Publication number Publication date
CN114728919B (zh) 2025-12-30
AU2020380926B2 (en) 2026-07-16
IL292693B1 (en) 2026-05-01
AU2020380926A1 (en) 2022-05-26
CA3159633A1 (en) 2021-05-14
WO2021092264A1 (en) 2021-05-14
IL292693A (en) 2022-07-01
JP2022554392A (ja) 2022-12-28
CN114728919A (zh) 2022-07-08
US20230002336A1 (en) 2023-01-05
EP4055011A1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
JP7712922B2 (ja) 炎症性障害を治療するためのMrgprX2アンタゴニスト
JP7827911B2 (ja) MrgprX2アンタゴニストおよびその使用
CN114728919B (zh) MrgprX2拮抗剂及其用途
AU2017213475B2 (en) SecA inhibitors and methods of making and using thereof
AU2007218596A1 (en) Stabilized pharmaceutical composition
TW200404531A (en) Synergistic combinations
JP2024543413A (ja) 結晶性イミダゾ[4,5-b]ピリジン化合物、医薬組成物、及び医学的状態を治療する際のそれらの使用
JP2019502686A (ja) 消化管括約筋機能障害の治療へのsGC刺激薬の使用
CN101500567B (zh) P38激酶抑制剂治疗精神障碍的用途
RU2670978C9 (ru) Полиморфные формы
EP4561551A1 (en) Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome
HK1206736B (en) Seca inhibitors and methods of making and using thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220610

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231023

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250922

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251205

R150 Certificate of patent or registration of utility model

Ref document number: 7787811

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150